Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Short term Debt: 2023-2025

Historic Short term Debt for Xeris Biopharma Holdings (XERS) over the last 2 years, with Mar 2025 value amounting to $12.0 million.

  • Xeris Biopharma Holdings' Short term Debt rose 1071.30% to $12.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $12.0 million, marking a year-over-year increase of 1071.30%. This contributed to the annual value of $15.1 million for FY2024, which is 20.97% down from last year.
  • Xeris Biopharma Holdings' Short term Debt amounted to $12.0 million in Q1 2025, which was down 20.81% from $15.1 million recorded in Q4 2024.
  • In the past 5 years, Xeris Biopharma Holdings' Short term Debt ranged from a high of $19.1 million in Q4 2023 and a low of $420,000 during Q2 2024.
  • For the 3-year period, Xeris Biopharma Holdings' Short term Debt averaged around $12.4 million, with its median value being $15.1 million (2024).
  • In the last 5 years, Xeris Biopharma Holdings' Short term Debt slumped by 97.48% in 2024 and then skyrocketed by 1,071.30% in 2025.
  • Over the past 3 years, Xeris Biopharma Holdings' Short term Debt (Quarterly) stood at $19.1 million in 2023, then fell by 20.97% to $15.1 million in 2024, then soared by 1,071.30% to $12.0 million in 2025.
  • Its Short term Debt stands at $12.0 million for Q1 2025, versus $15.1 million for Q4 2024 and $15.1 million for Q3 2024.